Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Oral entecavir highly effective in transgenic mouse model of HBV infection

March 22, 2002

Prague presentations describe good anti-HBV activity and favorable pharmacokinetics of MIV-210

March 22, 2002

Zelnorm/Zelmac approved in Canada and Brazil

March 20, 2002

Viramidine as an effective and safe liver-targeting ribavirin prodrug

March 19, 2002

KF-66854: a new prokinetic agent that acts via 5-HT4 receptors

March 18, 2002

FDA approval for new formulation of Visicol

March 18, 2002

Corvas and Schering-Plough describe new HCV protease inhibitors

March 14, 2002

Early access program initiated for Gilead's adefovir dipivoxil in chronic HBV

March 14, 2002

Sustained seroconversion reported in 24% of Japanese hepatitis B patients on Zadaxin

March 14, 2002

Serine protease inhibitors of HCV reported by Schering-Plough and Corvas

March 13, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...